Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Abstract Prolgolimab is a recombinant IgG1-based anti-PD-1 antibody, whose properties were improved by the introduction of the LALA mutation, and which has demonstrated high efficacy in patients with metastatic melanoma. This paper presents the results of comparative preclinical studies of antigen-b...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-72118-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|